Enlivex Historical Balance Sheet
ENLV Stock | USD 1.36 0.01 0.74% |
Trend analysis of Enlivex Therapeutics balance sheet accounts such as Total Current Liabilities of 3.6 M or Total Stockholder Equity of 25.2 M provides information on Enlivex Therapeutics' total assets, liabilities, and equity, which is the actual value of Enlivex Therapeutics to its prevalent stockholders. By breaking down trends over time using Enlivex Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Enlivex Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enlivex Therapeutics is a good buy for the upcoming year.
Enlivex Therapeutics Inventory |
|
Enlivex |
About Enlivex Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Enlivex Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Enlivex Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Enlivex Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Enlivex currently owns. An asset can also be divided into two categories, current and non-current.
Enlivex Therapeutics Balance Sheet Chart
Enlivex Therapeutics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Enlivex Therapeutics uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Enlivex Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year. Other Stockholder Equity is likely to climb to about 145.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.6 M in 2024. Add Fundamental
Total Assets
Total assets refers to the total amount of Enlivex Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Enlivex Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Enlivex Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Enlivex Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Long Term Debt
Long-term debt is a debt that Enlivex Therapeutics has held for over one year. Long-term debt appears on Enlivex Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Enlivex Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most accounts from Enlivex Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Enlivex Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.At this time, Enlivex Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year. Other Stockholder Equity is likely to climb to about 145.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.6 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 3.2M | 4.0M | 4.9M | 5.1M | Total Assets | 95.1M | 67.6M | 36.8M | 30.6M |
Enlivex Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Enlivex Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enlivex Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 17.6M | 40.4M | 95.1M | 67.6M | 36.8M | 30.6M | |
Other Current Liab | 5.5M | 3.7M | 3.2M | 4.0M | 4.9M | 5.1M | |
Total Current Liabilities | 6.0M | 4.4M | 4.7M | 6.6M | 6.1M | 3.6M | |
Total Stockholder Equity | 11.3M | 35.5M | 85.0M | 56.8M | 30.1M | 25.2M | |
Accounts Payable | 316K | 463K | 878K | 1.9M | 827K | 1.1M | |
Cash | 3.9M | 5.7M | 11.2M | 47.8M | 926K | 879.7K | |
Other Assets | (426.0) | 0.0 | 81K | 412K | 370.8K | 253.8K | |
Short Term Investments | 8.1M | 30.0M | 72.9M | 299K | 26.5M | 13.3M | |
Other Current Assets | 510K | 32.4M | 12.3M | 2.4M | 6.3M | 6.3M | |
Total Liab | 6.3M | 4.9M | 10.1M | 10.8M | 6.7M | 5.5M | |
Common Stock | 1.2M | 1.6M | 2.1M | 2.1M | 2.1M | 2.2M | |
Property Plant Equipment | 1.1M | 2.1M | 2.5M | 14.9M | 17.1M | 18.0M | |
Net Debt | (3.8M) | (5.5M) | (10.6M) | (43.0M) | 106K | 111.3K | |
Retained Earnings | (25.7M) | (37.5M) | (52.0M) | (83.0M) | (112.1M) | (106.5M) | |
Cash And Short Term Investments | 12.0M | 35.7M | 84.1M | 48.1M | 27.4M | 23.0M | |
Net Receivables | 2.4M | 1.2M | 2.2M | 647K | 229K | 217.6K | |
Common Stock Shares Outstanding | 8.6M | 13.2M | 17.9M | 18.4M | 18.6M | 19.5M | |
Liabilities And Stockholders Equity | 17.6M | 40.4M | 95.1M | 67.6M | 36.8M | 31.4M | |
Other Stockholder Equity | 37.1M | 70.4M | 133.8M | 136.6M | 138.9M | 145.9M | |
Total Current Assets | 16.4M | 38.1M | 86.4M | 52.3M | 33.8M | 28.5M | |
Property Plant And Equipment Net | 1.1M | 2.1M | 8.2M | 14.9M | 2.6M | 3.0M | |
Non Current Assets Total | 1.1M | 2.2M | 8.7M | 15.3M | 3.1M | 3.2M | |
Non Currrent Assets Other | (329K) | 8K | 482K | 105K | 179K | 188.0K | |
Property Plant And Equipment Gross | 648K | 2.1M | 10.2M | 18.4M | 6.6M | 4.3M | |
Accumulated Other Comprehensive Income | (2.3M) | (1.3M) | 977K | 1.1M | 1.3M | 1.3M | |
Non Current Liabilities Total | 298K | 499K | 5.4M | 4.2M | 686K | 651.7K | |
Net Tangible Assets | 11.3M | 35.5M | 85.0M | 56.8M | 65.4M | 32.8M | |
Net Invested Capital | 11.3M | 35.5M | 85.0M | 56.8M | 30.1M | 36.3M | |
Net Working Capital | 10.4M | 33.7M | 81.7M | 45.7M | 27.7M | 33.3M | |
Capital Stock | 1.2M | 1.6M | 2.1M | 2.1M | 2.1M | 1.8M |
Pair Trading with Enlivex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enlivex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enlivex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Enlivex Stock
0.7 | WU | Western Union | PairCorr |
0.87 | WKEY | Wisekey International Tech Boost | PairCorr |
0.67 | FUBO | FubotvInc Aggressive Push | PairCorr |
Moving against Enlivex Stock
0.55 | DIOD | Diodes Incorporated | PairCorr |
The ability to find closely correlated positions to Enlivex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enlivex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enlivex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enlivex Therapeutics to buy it.
The correlation of Enlivex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enlivex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enlivex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enlivex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Stocks Directory Find actively traded stocks across global markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Enlivex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enlivex Therapeutics. If investors know Enlivex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enlivex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Return On Assets (0.30) | Return On Equity (0.67) |
The market value of Enlivex Therapeutics is measured differently than its book value, which is the value of Enlivex that is recorded on the company's balance sheet. Investors also form their own opinion of Enlivex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enlivex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enlivex Therapeutics' market value can be influenced by many factors that don't directly affect Enlivex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.